Following earlier new-account rules requiring confirmation that funds originate from lawful offshore channels, some Hong Kong banks have begun seeking source-of-funds declarations from selected existing mainland China investment clients. HSBC Hong Kong has told affected clients to submit an Account Opening/Maintenance declaration via the HSBC Hong Kong app and update contact details by Sept 12. The declaration requires confirmation that investment funds come from lawful sources outside mainland

2026-08-18

Following earlier new-account rules requiring confirmation that funds originate from lawful offshore channels, some Hong Kong banks have begun seeking source-of-funds declarations from selected existing mainland China investment clients. HSBC Hong Kong has told affected clients to submit an Account Opening/Maintenance declaration via the HSBC Hong Kong app and update contact details by Sept 12. The declaration requires confirmation that investment funds come from lawful sources outside mainland China and notes the bank may disclose personal data to law enforcement or regulators. The notice warns that failure to submit by Aug 20 may result in suspension of investment services, and failure to submit by Sept 12 could lead to termination. An HSBC spokesperson on Aug 18 said the bank is following regulatory requirements and is asking affected mainland investors to self-declare and confirm their KYC and client due-diligence information is current; the requirement applies only to investment-service clients.

其他消息
2026-08-18

An LME measure of near-term supply tightness surged as copper resumed sharp volatility. The LME one-day contract traded at a $75/tonne premium to the next-day contract, the widest since January when the spread hit $100/tonne amid record LME benchmark prices. The tightness largely reflected traders rerouting several hundred thousand tonnes of copper to the United States ahead of a Trump administration decision on import tariffs. Tom/next spreads widened sharply on Tuesday, signalling short-positi

2026-08-18

Betta Pharmaceuticals shares hit the down limit after EyePoint Pharmaceuticals’ US-listed stock plunged ~67% overnight following a Phase III failure of fulonib in wAMD; Betta holds Greater China rights to the candidate.